AlcHepNet ITAALD Trial | Multi-center clinical study advancing research in severe alcohol-associated hepatitis | Collaborative. Innovative. Patient-focused.
Joined January 2019
- Tweets16
- Following67
- Followers49
- Likes7
New publication alert!
Check out this new AlcHepNet/ITAALD-related publication on adaptive clinical trial design: pubmed.ncbi.nlm.nih.gov/4253…
The new ARDaC Portal is live!
Our data commons allows you to explore AlcHepNet & TREAT data, expanded proteomics datasets, and the AI-powered Anagine© Summary Report.
🔗 portal.ardac.org
Need access? [email protected]
#ARDaC #ClinicalResearch
AlcHepNet retweeted
Fine-tuning our @RSAposts presentation with Dr Thomas Kerr this weekend
On June 22 in San Antonio, we’ll present @AlcHepNet data examining diagnostic and behavioral predictors of return to drinking in moderate AH
Looking forward to the discussion
researchgate.net/publication… – at Fort Worth, TX
AlcHepNet retweeted
Proud to share our latest @AlcHepNet work in @ACERjournal
doi.org/10.1111/acer.70263
Among 518 survivors of alcohol-associated hepatitis, >20% returned to drinking by 3 months
AH care must integrate early, proactive AUD treatment
Supports @NIAAAnews ITAALD study rationale
AlcHepNet retweeted
@AlcHepNet paper out in Hepatology. Good read!
journals.lww.com/hep/fulltex…
The ITAALD trial is now enrolling patients with sAH.
This multicenter, randomized study evaluates IL-22 (F-652) vs prednisone + integrated AUD therapy (acamprosate + counseling) to improve liver & alcohol-related outcomes.
Learn more clinicaltrials.gov/study/NCT…
New publication out in JHEP Reports from @Bernd_Schnabl and team! 🎉
Peptide YY reduces Candida albicans cytotoxicity in alcohol-associated liver disease—opening new directions for microbiome-targeted therapies. 🔗 jhep-reports.eu/article/S258…
AlcHepNet retweeted
@AlcHepNet work in @JAMANetworkOpen led by @LaurenNephewMD @nagachalasani
Only 37% of AH pts referred for transplant
Neighborhood disadvantage shapes referral - we’re missing pts before they even reach transplant. Referral is key equity leverage point
jamanetwork.com/journals/jam…
AlcHepNet retweeted
Excited to share that the ITAALD trial has been officially launched!
This trial is investigating IL-22 followed by AUD tx in severe alcohol-associated hepatitis, building on promising phase 2 results:
pubmed.ncbi.nlm.nih.gov/3177…
@AlcHepNet @NIAAAnews @Dr_Vijay_Shah @juanpabloarab
First post + big milestone! 🎉
The ITAALD Trial has officially enrolled its first patient in January. Huge thanks to our investigators and site teams for making this happen.
We’re just getting started. #ITAALD #ClinicalTrials
ITAALD Study now OPEN for enrollment!
We’re enrolling sAH patients (MELD 20–35). If you have patients who may qualify, we’d love to connect.
Active sites: IU, VCU, UTSW, Cleveland Clinic, Mayo Clinic, University of Louisville.
For more details:
alchepnet.org/
New publication 🚨
“Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis” by @LaurenNephewMD highlights disparities in transplant referral access.
#HealthEquity #Hepatology
🚨 New website update!
The AlcHepNet website now has a refreshed design and expanded content. Learn more about our ongoing clinical trial and the investigators advancing alcohol-associated hepatitis research.
Take a look 👇
alchepnet.org/
#ITAALD #ClinicalTrials
New in @Hepatology: In >218K U.S. patients, AUD pharmacotherapy was linked to fewer hospitalizations and lower alcohol-related costs —greatest savings in advanced liver disease.journals.lww.com/hep/abstrac…
First post + big milestone! 🎉
The ITAALD Trial has officially enrolled its first patient in January. Huge thanks to our investigators and site teams for making this happen.
We’re just getting started. #ITAALD #ClinicalTrials